Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 5:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo fluticasone Clear all
Recruiting Phase 4 Interventional

Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea

NCT02630121
View directory record Official record
Conditions
Sleep Apnea, Chronic Nasal Congestion
Interventions
Oxymetazoline Hydrochloride, Placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Sep 28, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available

Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler

NCT02980133
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate, Fluticasone Propionate/Salmeterol, Placebo MDPI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
77
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 59 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 28, 2026, 5:56 PM EDT
Completed Phase 4 Interventional Results available

Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations

NCT01430403
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Inhaled Corticosteroid Boost Therapy (ICS), Placebo omalizumab, Placebo fluticasone
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 17 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 28, 2026, 5:56 PM EDT
Completed Phase 2 Interventional

A 12-Week Study in Adult Subjects With Asthma

NCT01516086
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate (FP)
Drug
Lead sponsor
Dey
Industry
Eligibility
18 Years to 60 Years
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Rock Hill, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Sep 28, 2026, 5:56 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Pharmacokinetics of QAW039

NCT01253603
View directory record Official record
Conditions
Persistent Asthma
Interventions
QAW039 capsules once daily for 28 days, Placebo to QAW039 capsules once daily for 28 days, Fluticasone propionate inhaler twice daily for 28 days
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
18
States / cities
Encinitas, California • Huntington Beach, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 28, 2026, 5:56 PM EDT
Completed Phase 2 Interventional

A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease

NCT00403286
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Fluticasone Propionate/Formoterol Fumarate, Fluticasone Propionate, Formoterol Fumarate, Fluticasone Propionate/Salmeterol Xinafoate, Placebo
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
49
States / cities
Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2009 · Synced Sep 28, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients

NCT01836471
View directory record Official record
Conditions
Asthma
Interventions
QAW039, Placebo QAW039, Fluticasone 250 mcg, Fluticasone 100 mcg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
30
States / cities
Encinitas, California • Huntington Beach, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 28, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available

HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents

NCT01147848
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate/Vilanterol Inhalation Powder, Fluticasone propionate/salmeterol Inhalation Powder, Placebo (1), Placebo (2)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
25
States / cities
Huntington Beach, California • Los Angeles, California • Riverside, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 28, 2026, 5:56 PM EDT
Completed Phase 4 Interventional Results available

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03474081
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/UMEC/VI, Tiotropium, Albuterol/salbutamol, Placebo to match FF/UMEC/VI, Placebo to match tiotropium, ELLIPTA inhaler, HANDIHALER, MDI
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
33
States / cities
Andalusia, Alabama • Huntington Beach, California • Sacramento, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Sep 28, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available

DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)

NCT01868009
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
ELLIPTA, DISKUS
Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
17
States / cities
Jasper, Alabama • Riverside, California • Clearwater, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Sep 28, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01817764
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium/vilanterol, Fluticasone propionate/salmeterol, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
9
States / cities
Jasper, Alabama • Phoenix, Arizona • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 28, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily

NCT01147744
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate 100mcg via ACCUHALER/DISKUS, GSK2190915 100mg, GSK2190915 10mg, GSK2190915 300mg, GSK2190915 30mg, Montelukast 10mg, Placebo GSK2190915 one tablet, Placebo montelukast, Placebo fluticasone propionate via ACCUHALER/DISKUS, Placebo GSK2190915 two tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older · Female only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Birmingham, Alabama • Huntington Beach, California • Newport Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2017 · Synced Sep 28, 2026, 5:56 PM EDT
Active, not recruiting Phase 4 Interventional

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

NCT06572228
View directory record Official record
Conditions
Asthma
Interventions
dupilumab, Matching Placebo, ICS/LABA
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
51
States / cities
Bakersfield, California • La Jolla, California • Lancaster, California + 47 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 28, 2026, 5:56 PM EDT
Completed Phase 4 Interventional Results available

Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.

NCT00570492
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Fluticasone furoate nasal spray, Placebo nasal spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 8 Years
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
50
States / cities
Oxford, Alabama • Little Rock, Arkansas • Huntington Beach, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Sep 28, 2026, 5:56 PM EDT
Completed Phase 4 Interventional Results available

A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis

NCT00609674
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Fluticasone furoate nasal spray, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
12
States / cities
Baltimore, Maryland • Wheaton, Maryland • North Dartmouth, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 28, 2026, 5:56 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)

NCT04281108
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
Drug · Procedure
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
48
States / cities
Anniston, Alabama • Dothan, Alabama • Mobile, Alabama + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Sep 28, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis

NCT00929968
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Placebo, VAK694, Fluticasone
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 28, 2026, 5:56 PM EDT
Completed Phase 2 Interventional

A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01168310
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Fluticasone Propionate/Formoterol Fumarate, Formoterol Fumarate, Placebo
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Days and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
23
States / cities
Phoenix, Arizona • Fullerton, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced Sep 28, 2026, 5:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen

NCT00791973
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
fluticasone furoate, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 7, 2014 · Synced Sep 28, 2026, 5:56 PM EDT
Completed Phase 4 Interventional Results available

Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease

NCT00984659
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone propionate/salmeterol combination product, Salmeterol, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
39
States / cities
Jasper, Alabama • Mobile, Alabama • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 28, 2026, 5:56 PM EDT
Completed Phase 3 Interventional

Advair Pediatric Once-Daily

NCT00920959
View directory record Official record
Conditions
Asthma
Interventions
FP 100mcg, FSC 100/50mcg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 11 Years
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
141
States / cities
Ozark, Alabama • Tucson, Arizona • Little Rock, Arkansas + 118 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Sep 28, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Results available

Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease

NCT02573870
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Batefenterol + Fluticasone Furoate, Placebo, Albuterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Phoenix, Arizona • Hollywood, Florida • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Sep 28, 2026, 5:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis

NCT02402465
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Placebo, Fluticasone propionate, Fluticasone/Azelastine nasal spray, Nasal Allergen Challenge
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 28, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Results available

An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

NCT01854047
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, placebo, ICS/LABA therapy, Salbutamol/albuterol, Levosalbutamol/levalbuterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
50
States / cities
Fullerton, California • Huntington Beach, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Sep 28, 2026, 5:56 PM EDT